Description

DESIROX 250 MG (1X30)

Indications

DESIROX (deferasirox) is primarily indicated for the treatment of chronic iron overload due to blood transfusions in patients with beta-thalassemia major or other anemias. It is also used in patients with non-transfusion-dependent thalassemia syndromes who have significant iron overload. The medication is designed to reduce excess iron levels in the body, which can lead to serious complications if left untreated.

Mechanism of Action

DESIROX is an oral iron chelator that binds to free iron in the bloodstream. By forming a stable complex with iron, it facilitates its excretion through the kidneys. This process helps to lower the overall iron burden in patients who suffer from conditions that cause iron overload, particularly those requiring frequent blood transfusions. The chelation of iron prevents the formation of reactive oxygen species that can lead to cellular damage and organ dysfunction.

Pharmacological Properties

DESIROX is characterized by its high affinity for ferric iron, which allows it to effectively bind iron in a non-toxic manner. The pharmacokinetics of DESIROX reveal that it is absorbed in the gastrointestinal tract, with peak plasma concentrations occurring approximately 1 to 4 hours after administration. The drug is metabolized primarily in the liver, and its metabolites are excreted via the urine. The elimination half-life of DESIROX is approximately 8 to 16 hours, allowing for once-daily dosing in most patients.

Contraindications

DESIROX is contraindicated in patients with a known hypersensitivity to deferasirox or any of the excipients in the formulation. It should not be used in patients with severe renal impairment (creatinine clearance less than 40 mL/min) or in those with active hepatic disease. Additionally, it is not recommended for use in patients with a history of gastrointestinal bleeding or those who are pregnant or breastfeeding unless the potential benefits outweigh the risks.

Side Effects

The use of DESIROX may be associated with several side effects. Common adverse reactions include gastrointestinal disturbances such as diarrhea, nausea, and abdominal pain. Other potential side effects include skin rashes, elevated liver enzymes, and renal impairment. Serious adverse effects, although rare, may include agranulocytosis and hepatic failure. Patients should be monitored regularly for these side effects, especially during the initial months of therapy.

Dosage and Administration

The recommended starting dose of DESIROX for adults and children over 2 years of age is typically 20 mg/kg body weight once daily. The dose may be adjusted based on the patient’s response and serum ferritin levels, with a maximum dose not exceeding 40 mg/kg per day. It is important to take DESIROX on an empty stomach, at least 30 minutes before food, to enhance absorption. The tablets should be swallowed whole with a glass of water and should not be crushed or chewed.

Interactions

DESIROX may interact with various medications, which can affect its efficacy or increase the risk of side effects. Co-administration with antacids or medications containing aluminum may reduce the absorption of DESIROX. It is important to separate the administration of these agents by at least 2 hours. Additionally, concomitant use of other iron supplements should be avoided, as this may lead to increased iron levels and toxicity. Patients should inform their healthcare provider of all medications they are taking to manage potential interactions effectively.

Precautions

Before initiating treatment with DESIROX, a thorough assessment of the patient’s renal and hepatic function is essential. Regular monitoring of serum ferritin levels and complete blood counts is recommended to assess treatment efficacy and detect any adverse effects. Patients should be advised to report any signs of infection, unusual bruising, or bleeding, which may indicate serious side effects. It is also important to educate patients about the signs of iron overload and the need for adherence to therapy.

Clinical Studies

Clinical studies have demonstrated the efficacy of DESIROX in reducing iron overload in patients with beta-thalassemia and other anemias. In a pivotal trial, patients treated with DESIROX showed a significant reduction in serum ferritin levels compared to those receiving standard care. Long-term studies have indicated that DESIROX is effective in maintaining lower iron levels, thereby reducing the risk of complications associated with iron overload, including cardiac and liver damage. The safety profile of DESIROX has been established through extensive clinical trials, confirming its role as a valuable therapeutic option in managing chronic iron overload.

Conclusion

DESIROX 250 MG is an effective oral iron chelator that plays a crucial role in managing chronic iron overload in patients with conditions such as beta-thalassemia. Its mechanism of action, pharmacological properties, and clinical efficacy make it a vital component of therapy for these patients. However, careful monitoring for side effects and drug interactions is essential to ensure patient safety and treatment success. As with any medication, it is important for patients to follow their healthcare provider’s instructions and report any concerning symptoms promptly.